I. Background

HHS is announcing the availability of a draft ''Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.'' This document describes the HHS Secretary's enforcement policy regarding the use of certain peptide bulk drug substances in compounding pursuant to section 503A of the FD&C Act while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking (21 U.S.C. 353a).

Compounding is generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. Although compounded drugs can serve an important medical need for certain patients, they also may pose risks to patients. However, based on the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products. Therefore, to expand and improve patient access, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A. FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence.

HHS may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises with a compounded drug product within the scope of this policy. The draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances does not establish any rights for any person and is not binding on HHS or the public.

II. Paperwork Reduction Act of 1995

This policy contains no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3521) is not required.

III. Electronic Access

Persons with access to the internet may obtain the document at *https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf*, or *https://www.regulations.gov*. Use the HHS website listed in the previous sentence to find the most current version of the policy.

Robert F. Kennedy, Jr.,

Secretary, Department of Health and Human Services.

[FR Doc. 2026–22192 Filed 10–28–26; 11:15 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Board on Medical Rehabilitation Research.

This will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: *https://videocast.nih.gov/*.

Name of Committee: National Advisory Board on Medical Rehabilitation Research

Date: December 6–7, 2027.

Time: December 06, 2027, 10:00 a.m. to 3:00 p.m.

Agenda: NICHD Director's Report, NCMRR Director's report; Election of a new Board Chair-Elect; Scientific Talk on Rehabilitation Research topic.

Address: Eunice Kennedy Shriver National Institute of Child, Health and Human Development, National Institutes of Health, 6710 B Rockledge Drive, Bethesda, MD 20817.

Meeting Format: In Person and Virtual Meeting.

Time: December 07, 2027, 10:00 a.m. to 2:00 p.m.

Agenda: Update on NIH policy issues; Discussion of Research support and Training; Scientific Talk; Planning for Next NABMRR Meeting.

Address: Eunice Kennedy Shriver National Institute of Child, Health and Human Development, National Institutes of Health, 6710 B Rockledge Drive, Bethesda, MD 20817.

Meeting Format: In Person and Virtual Meeting.

Contact Person: Joseph Bonner, Ph.D., National Center for Medical Rehabilitation Research, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, 6710 B Rockledge Drive, Bethesda, MD 20817, (301) 827–8303, *joe.bonner@nih.gov.*

Registration is not required to attend this meeting.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Persons listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at *https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx* for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *https://www.nichd.nih.gov/about/advisory/nabmrr,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: October 27, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–22195 Filed 10–29–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council.

Date: May 12, 2027.

Open: May 12, 2027, 8:30 a.m. to 12:00 p.m.

Agenda: Council Business.

Open: May 12, 2027, 1:00 p.m. to 2:30 p.m.

Agenda: KUH, DEM, DDN Open session.

Closed: May 12, 2027, 1:00 p.m. to 2:30 p.m.

Agenda: DEM, DDN, KUH Closed session to review and evaluate grant applications.

Closed: May 12, 2027, 3:45 p.m. to 4:00 p.m.

Agenda: Reports of Subcommittees and Consideration of Applications.

Address: Shady Grove Conference Center, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850.

Meeting Format: In Person and Virtual Meeting.

Contact Person: Karl F. Malik, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, *malikk@niddk.nih.gov.*

In the interest of security, NIH has procedures at *https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx* for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/national-diabetes-digestive-kidney-diseases-advisory-council,* where an agenda and any additional information for the meeting will be posted when available.

Dated: October 26, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–22196 Filed 10–29–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS–2026–0694]

Notice of Order Regarding Exclusion and Removal of Acronis Products From Federal Civilian Executive Branch Information Technology Systems and Procurements

AGENCY: Department of Homeland Security (DHS).

ACTION: Notice of order.

SUMMARY: The Department of Homeland Security is publishing notice of the Secretary of Homeland Security's issuance of an order excluding Acronis AG and all affiliated entities, as well as any covered articles directly or indirectly supplied by them (Acronis covered articles) from federal civilian agency procurements; and, removing all Acronis covered articles from civilian agency information technology systems.

FOR FURTHER INFORMATION CONTACT: FASCSA Order Implementation Team CISA Cybersecurity Division, *fascsa.orders@cisa.dhs.gov.*

SUPPLEMENTARY INFORMATION: Pursuant to the authority granted by the Federal Acquisition Supply Chain Security Act of 2018, 41 U.S.C. 1321–1328, and implementing regulations at 41 CFR 201–1, following review of the Federal Acquisition Security Council Recommendation and affiliated evidence, the Secretary of Homeland Security has ordered: (1) exclusion of information technology products developed by Acronis, Inc., Acronis SCS, and affiliated entities as defined in 48 CFR 2.101, from federal civilian executive branch procurements; and (2) to remove said information technology products from federal civilian executive branch information technology systems.

A copy of the signed order is contained in the accompanying Appendix and can be found at *https://www.regulations.gov* by searching for DHS Docket Number DHS–2026–0694.

Kateland R. Jackson,

Principal Deputy General Counsel, U.S. Department of Homeland Security.

BILLING CODE 9111–LF–P

Appendix